Konferenzen  >  Medizin & Gesundheitswesen  >  Onkologie  >  Frankreich

The European Association for Cancer Research

Our popular Liquid Biopsies series returns for its fourth edition to bring together a slate of recognised experts who will explore how complex multi-modal liquid biopsy assays could be taken from the laboratory into clinical practice. Topics to be covered include the implementation of liquid biopsy in clinical trials, the various applications for CTCs, the basic biology of biomarker discovery, new techniques enhancing liquid biopsy, the integration of multiple blood-based analytes for multi-modal biomarkers, and how artificial intelligence can be applied to the field. This conference is suitable for a wide audience including translational scientists, researchers working in genetics, biology, molecular pathology, bioengineering, and data science, as well as clinical and non-clinical trainees, primary care physicians, radiologists, patient advocates, and colleagues from industry working in biotechnology, diagnostics, and pharmaceuticals.

Conference Officer: Hannah Barrs;     Tel.: [N/A];     Email: hannah.barrs@eacr.org

liquid biopsy, cancer research, oncology, translational research, clinical trials, clinical practice, early detection of cancer, cancer screening techniques, multi-modal assays, treatment efficacy vs resistance, treatment toxicity, cell-free DNA, cfRNA, CTCs, extracellular vesicles, extracellular proteins, blood-based analytes, AI in cancer detection and screening

The European Association for Cancer Research

This meeting will explore the burgeoning field of cancer persister cells, a rare subset of cells which have emerged over the last decade as a significant factor in cancer treatment failure. Unlike resistance cells, which harbour genetic alterations enabling survival despite therapy, persister cells exhibit transient drug tolerance through reversible, non-mutational mechanisms. Our conference on this topic will bring together investigators from across the world to delve into molecular mechanisms, therapeutic targets, and emerging clinical implications of cancer persister cells, fostering collaboration and community-building in this pivotal and rapidly growing area of research.

Email: christopher.iliffe@eacr.org

cancer research, oncology, cancer persister cells, cancer resistant cells, non-genetic drug resistance, treatment response, treatment success, treatment failure, molecular mechanisms of resistance and persistence, novel study methodologies, targeting vulnerabilities within persister cells, clinical implications and applications

Pharmakologie und Arzneimittelentwicklung,    Molekularbiologie